Core Viewpoint - Valhi, Inc. is set to announce its first quarter 2025 earnings on May 8, 2025, after market close, pending the completion of quarter-end closing procedures [1] Company Overview - Valhi, Inc. operates in multiple industries, including chemicals (specifically TiO2), component products (such as security products and recreational marine components), and real estate management and development [1] Investor Relations - The contact for investor relations is Bryan A. Hanley, who serves as the Senior Vice President and Treasurer, with a contact number of 972-233-1700 [1]

Core Viewpoint - VitalHub Corp. has announced a cash acquisition of Induction Healthcare Group PLC, valuing Induction at approximately £9.7 million, with each shareholder entitled to receive £0.10 in cash for each share held [1] Company Overview - Induction provides software solutions that enhance care delivery and patient journeys in hospitals, allowing healthcare providers to deliver care both remotely and face-to-face [3][16] - Key products include Zesty, a patient engagement platform, and Attend Anywhere, a video consultation platform [4][5] Financial Performance - For FY24, Induction reported revenues of £14.4 million, a gross margin of 78.4%, and an adjusted EBITDA loss of £0.3 million [6] - For H1 FY25, revenues were £5.4 million, with a gross margin of 78.2% and an adjusted EBITDA loss of £0.9 million [7] Strategic Rationale - VitalHub views Induction's Zesty platform as complementary to its existing offerings, aiming to enhance product diversity and improve patient outcomes [8] - The acquisition is expected to expand VitalHub's market reach in the UK, Europe, Canada, the Middle East, and Australia [9] - Induction is anticipated to benefit from being part of a larger, well-capitalized enterprise, enabling effective implementation of strategic initiatives [10] Acquisition Details - The acquisition will be executed through a court-approved scheme of arrangement, requiring approval from Induction shareholders and the Court [11][12] - Induction's directors recommend shareholders vote in favor of the scheme, with irrevocable commitments received for approximately 44.3% of Induction's shares [13] - The transaction is expected to close by July 31, 2025, with a long stop date of September 30, 2025 [13]

Core Insights - VitalHub Corp. reported a significant increase in Annual Recurring Revenue (ARR), which rose by 59% year-over-year to $71.1 million [1][6][9] - Total revenue for the year increased by 51% year-over-year, reaching $20.6 million [1][7] - Adjusted EBITDA grew by 27% year-over-year to $5.0 million, reflecting a strong operational performance [1][9] Financial Performance - The company achieved organic ARR growth of 15% and acquisition ARR growth of 40% for the year [3][6] - In Q4 2024, the company reported a sequential net new organic ARR of $2.6 million, with balanced contributions from its EHR suite in Canada and patient flow solutions in the UK [3] - Total revenue for 2024 was $68.6 million, an increase of 31% compared to the previous year [6][7] Acquisitions and Growth Strategy - VitalHub completed four acquisitions in 2024, contributing an additional $17.9 million in ARR [3][6] - The company is focused on integrating new solutions and enhancing operational efficiency post-acquisition [3] - VitalHub's pro forma cash balance is approximately $90 million, indicating strong cash generation and readiness for further M&A activities [3][8] Operational Metrics - Gross profit margin remained strong at 81%, although it slightly decreased from 83% in the prior year [6][7] - The company reported a net income before income taxes of $5.9 million, an increase of 11% year-over-year [6][9] - Adjusted EBITDA as a percentage of revenue was 26%, compared to 25% in the prior year, indicating improved profitability [8][9] Market Position and Future Outlook - VitalHub serves over 1,000 clients globally, with a robust product suite aimed at health and human services providers [10] - The company is positioned for sustained growth through both organic opportunities and an aggressive M&A strategy [10] - VitalHub's quarterly investor conference call is scheduled for March 28, 2025, to discuss further developments [3][4]

Core Viewpoint - VitalHub Corp. is set to release its financial results for Q4 2024 on March 27, 2025, followed by a conference call on March 28, 2025, at 9:00 am EST [1] Company Overview - VitalHub is a leading software company focused on empowering health and human services providers globally, with a product suite that includes electronic health records, operational intelligence, and workforce automation solutions [2] - The company serves over 1,000 clients across the UK, Canada, and other regions, and has a robust growth strategy that includes both organic opportunities and an aggressive M&A plan [2] - VitalHub is headquartered in Toronto and employs over 500 individuals globally, including a dedicated Innovations Lab in Sri Lanka [2]

Financial Performance - Valhi reported net income of $22.8 million ($0.80 per share) in Q4 2024, a significant increase from $4.9 million ($0.17 per share) in Q4 2023[1]. - For the full year 2024, net income attributable to Valhi stockholders was $108.0 million ($3.79 per share), compared to a net loss of $9.9 million ($0.35 per share) in 2023[1]. - Total net sales for the three months ended December 31, 2024, increased to $480.9 million, up from $453.0 million in the same period of 2023, representing a growth of 6%[17]. - The company reported a total operating income of $56.7 million for the three months ended December 31, 2024, compared to $17.2 million in the same period of 2023[17]. - Basic and diluted net income per share increased to $0.80 for the three months ended December 31, 2024, compared to $0.17 in the same period of 2023[17]. Chemicals Segment Performance - The Chemicals Segment's net sales reached $423.1 million in Q4 2024, up $23.0 million (6%) from Q4 2023, and $1.9 billion for the full year 2024, an increase of $220.6 million (13%) compared to 2023[3]. - TiO2 sales volumes increased by 4% in Q4 2024 and 20% for the full year 2024 compared to the same periods in 2023[3]. - The Chemicals Segment's operating income was $32.6 million in Q4 2024, compared to an operating loss of $1.6 million in Q4 2023, and $138.5 million for the full year 2024, compared to a loss of $41.1 million in 2023[5]. - The chemicals segment reported net sales of $423.1 million for the three months ended December 31, 2024, compared to $400.1 million in 2023, reflecting a 6% increase[17]. - The overall percentage change in TiO2 net sales for the year ended December 31, 2024, was 13%, driven by a 2% increase in product pricing[18]. - The Chemicals Segment's production rates increased to 96% of practical capacity utilization in 2024, compared to 72% in 2023, leading to a significant reduction in unabsorbed fixed production costs[5]. Component Products Segment Performance - The Component Products Segment's net sales were $38.4 million in Q4 2024, down from $43.2 million in Q4 2023, and $145.9 million for the full year 2024, compared to $161.3 million in 2023[7]. Real Estate Management and Development Segment Performance - The Real Estate Management and Development Segment reported net sales of $19.4 million in Q4 2024, up from $9.7 million in Q4 2023, but full year sales decreased to $71.8 million from $93.9 million in 2023[8]. - Real estate management and development segment net sales rose to $19.4 million in Q4 2024, compared to $9.7 million in Q4 2023, marking a 100% increase[17]. Interest Expense - Interest expense increased by $6.4 million in Q4 2024 and $21.6 million for the full year compared to 2023, primarily due to higher interest rates and increased debt from the LPC acquisition[10]. - Interest expense decreased to $13.3 million in Q4 2024 from $6.9 million in Q4 2023, indicating improved financial management[17]. Acquisition Impact - The acquisition of the 50% joint venture interest in Louisiana Pigment Company resulted in a non-cash gain of $64.5 million ($33.6 million, or $1.18 per share) recognized in Q3 2024[2].

Core Insights - Valhi, Inc. reported a significant increase in net income for the fourth quarter and full year of 2024, with net income attributable to stockholders reaching $22.8 million ($0.80 per share) in Q4 2024, compared to $4.9 million ($0.17 per share) in Q4 2023. For the full year, net income was $108.0 million ($3.79 per share), a turnaround from a net loss of $9.9 million ($0.35 per share) in 2023 [1][15]. Chemicals Segment Performance - The Chemicals Segment's net sales in Q4 2024 were $423.1 million, a 6% increase from $400.1 million in Q4 2023. For the full year, net sales reached $1.9 billion, up 13% from $1.666 billion in 2023 [3][15]. - The increase in net sales for the Chemicals Segment was driven by higher sales volumes and average selling prices for TiO2, with sales volumes up 4% in Q4 2024 and 20% for the full year compared to the previous year [3][17]. - Operating income for the Chemicals Segment improved significantly, reaching $32.6 million in Q4 2024 compared to an operating loss of $1.6 million in Q4 2023. For the full year, operating income was $138.5 million, a recovery from a loss of $41.1 million in 2023 [4][15]. Component Products Segment Performance - The Component Products Segment reported net sales of $38.4 million in Q4 2024, down from $43.2 million in Q4 2023. For the full year, net sales were $145.9 million, compared to $161.3 million in 2023 [7][15]. - Operating income for this segment decreased to $4.9 million in Q4 2024 from $7.4 million in Q4 2023, and for the full year, it fell to $17.0 million from $25.4 million in 2023, primarily due to lower sales and gross margins [7][15]. Real Estate Management and Development Segment Performance - The Real Estate Management and Development Segment saw net sales of $19.4 million in Q4 2024, up from $9.7 million in Q4 2023. However, for the full year, net sales decreased to $71.8 million from $93.9 million in 2023 [8][15]. - The decrease in full-year sales was attributed to a slower pace of development activities due to delays in obtaining necessary permits and approvals [8]. Acquisition Impact - The Chemicals Segment's acquisition of the 50% joint venture interest in Louisiana Pigment Company (LPC) was completed on July 16, 2024, resulting in LPC becoming a wholly-owned subsidiary. This acquisition contributed a non-cash gain of $64.5 million in net income for the full year of 2024 [2][15]. Financial Overview - Total net sales for Valhi, Inc. were $480.9 million in Q4 2024, compared to $453.0 million in Q4 2023. For the full year, total net sales increased to $2.1 billion from $1.921 billion in 2023 [15]. - Interest expense increased significantly due to higher interest rates and debt levels associated with the LPC acquisition, rising by $6.4 million in Q4 and $21.6 million for the full year compared to 2023 [10][15].

Core Points - Valhi, Inc. has declared a regular quarterly dividend of $0.08 per share on its common stock [1] - The dividend is payable on March 28, 2025, to stockholders of record at the close of business on March 17, 2025 [1] - Valhi, Inc. operates in the chemicals, component products, and real estate management and development industries [1]

Core Viewpoint - VitalHub Corp. has successfully closed a bought deal public offering, raising approximately $34.5 million through the sale of 3,165,145 common shares at a price of $10.90 per share, including the full exercise of the over-allotment option [1][2]. Group 1: Offering Details - The offering was conducted by a syndicate of underwriters led by Cormark Securities Inc., along with TD Securities Inc., Canaccord Genuity Corp., and Beacon Securities Limited [1]. - The common shares were qualified for distribution in Ontario, British Columbia, and Alberta through a short form prospectus [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be allocated towards the company's growth initiatives, specifically targeting acquisitions of third-party enterprises in the healthcare industry that provide synergistic opportunities [2]. Group 3: Company Overview - VitalHub is a leading software company focused on empowering health and human services providers globally, with a product suite that includes electronic health records, operational intelligence, and workforce automation solutions [4]. - The company serves over 1,000 clients across the UK, Canada, and other regions, and has a robust growth strategy that includes both organic opportunities and an aggressive M&A plan [4].

Core Viewpoint - VitalHub Corp. has filed a final short form prospectus for a bought deal public financing, aiming to distribute 2,752,300 common shares at a price of $10.90 per share, with an additional 412,845 shares available through an over-allotment option [2]. Group 1: Offering Details - The offering price for the common shares is set at $10.90 each [2]. - The expected closing date for the offering is around January 9, 2025, pending regulatory approval [2]. Group 2: Company Overview - VitalHub is a leading software company focused on health and human services, providing a comprehensive product suite that includes electronic health records and operational intelligence [5]. - The company serves over 1,000 clients across various regions, including the UK and Canada, and has a robust growth strategy that includes both organic growth and an aggressive M&A plan [5]. - VitalHub is headquartered in Toronto and employs over 500 people globally, with a dedicated innovations lab in Sri Lanka [5].

Core Viewpoint - VitalHub Corp. has amended and expanded its credit facilities with The Bank of Nova Scotia, increasing its total committed borrowing capacity from $33 million to $65 million, enhancing the company's financial flexibility for growth opportunities [1][2]. Financial Details - The amended credit facilities include a $60 million term facility and a $5 million revolving facility, with the potential to increase borrowing by an additional $10 million through an accordion facility, which remains undrawn as of the announcement date [2]. - The company currently holds over $50 million in cash, in addition to cash generated from operations, positioning it well for value creation through organic growth and strategic capital deployment [3]. Company Overview - VitalHub is a leading software company focused on empowering health and human services providers globally, offering a comprehensive product suite that includes electronic health records, operational intelligence, and workforce automation solutions [3]. - The company serves over 1,000 clients across the UK, Canada, and other regions, and has a robust growth strategy that includes both organic opportunities and an aggressive M&A plan [3].